Biovica, active in cancer diagnostics, today announces that Anders Morén has been appointed as the company’s Chief Financial Officer (CFO). Anders Morén will begin his new position on January 1, 2023.
Most recently, Anders Morén comes from the global pharmaceutical company Gilead where he was responsible for the finance function for a large part of Europe, Middle East and Africa (EMEA, with over SEK 10 billion in annual sales).
"I am very happy to welcome Anders Morén to Biovica. Among other things, he has participated in several successful launches at Gilead, experiences that will be very valuable to us when we launch DiviTum®TKa on the American market. I am very proud of the strong team Biovica has built and am humbled by the competent people we have managed to attract," said Anders Rylander, CEO of Biovica.
"I am very much looking forward to being part of the exciting journey that Biovica is facing. Based on my many years in the pharmaceutical industry, I hope to be able to contribute to the continued development of the company. The goal is to switch up and manage various opportunities to create future value, both for patients and shareholders,” said Anders Morén, the next CFO of Biovica.
Anders Morén succeeds Cecilia Driving, who, as previously announced, is leaving Biovica on December 31, 2022.
Biovica – Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information please visit: www.biovica.com.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
This cookie is installed by Google Analytics.
A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Hotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
Hotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.